Key points are not available for this paper at this time.
Among patients with previously treated advanced renal-cell carcinoma, overall survival was longer and fewer grade 3 or 4 adverse events occurred with nivolumab than with everolimus. (Funded by Bristol-Myers Squibb; CheckMate 025 ClinicalTrials.gov number, NCT01668784.).
Building similarity graph...
Analyzing shared references across papers
Loading...
Robert J. Motzer
Bernard Escudier
Ray McDermott
New England Journal of Medicine
Harvard University
University of Washington
Johns Hopkins University
Building similarity graph...
Analyzing shared references across papers
Loading...
Motzer et al. (Fri,) studied this question.
www.synapsesocial.com/papers/69d94c0e00ab073a27835e4f — DOI: https://doi.org/10.1056/nejmoa1510665